What Vizzhy does

Vizzhy Inc. is a privately held preventive health intelligence platform focused on cardiac and cardiometabolic disease, operational in Austin, Texas with an India launch in progress. The company builds the BioTwin, a computed patient-biology model that integrates 12+ biological data layers — including 3.5 billion genomic base pairs, 850K methylation sites, 20K+ gene expressions, 9,285 mass-spec proteins, 8,243 IPP-quantified proteins, 500+ metabolites, 1,200+ lipids, 6,476 microbial species, CGM glucose streams, 14-day WHOOP HRV/sleep data, imaging, and clinical labs — into a unified model that identifies cross-layer agreements, contradictions, and hidden disease mechanisms invisible to any single test.

The platform is delivered to clinicians through the Clinical Cognition Interface, a physician-facing console with nine screens spanning Patient Summary, Cross-Layer Findings, Treatment Readiness, Trajectory, Precision Interventions, Biological Deep Dive, Imaging Integration, Continuous Monitoring, and AI Clinical Reasoning Q&A. The product suite extends from the diagnostic BioTwin into five execution modules: Precision Drug Layer (Rx) for multi-layer drug assessment with genomic safety gates, Care Sequencing for time-ordered interventions, Nutrition Guidance (Nutr), Exercise Safety (Move), and Sensor Monitoring (Sens). Samples are collected locally and processed through certified labs in a global lab network; the platform operates independently from EMR systems.

Vizzhy runs a pilot-first B2B enterprise sales motion targeting hospital systems and cardiology practices, with structured 10-25 patient pilots before infrastructure commitments. Revenue mechanics combine hospital/practice subscription (B2B recurring) with usage-based multi-omics lab processing — pricing is quote-based. The company announced a strategic partnership and lead investment from Genie Healthcare on 2025-08-11 to accelerate U.S. clinical deployment, beginning in Texas. Founded by Dr. Vishnu Vardhan, a former orthopedic surgeon with two MIT master's degrees and developer of Hanooman (a multilingual multimodal LLM), Vizzhy operates with 51-100 employees. No public financials, customer logos, patents, or certifications are disclosed.

Name

Vizzhy

Legal name

Vizzhy Inc.

Website

https://vizzhy.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Vizzhy Inc. is an AI-native preventive health platform that computes patient biology across 12+ multi-omics layers (BioTwin) to identify hidden cardiovascular disease mechanisms. It serves hospital systems and cardiology practices through a physician-facing Clinical Cognition Interface with pilot-based enterprise sales.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Medical and Diagnostic Laboratories (6215), Custom Computer Programming Services (541511), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Chronic Disease Management Pathways (e.g., diabetes, CHF, COPD) (HLACAGAG)

akta.pro secondary industries

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

Keywords

• Multi-omics health platform
• Precision cardiology AI
• Biological terrain analysis
• Preventive cardiac care
• Clinical decision support

Headquarters

HQ city

Bengaluru

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hospital/Practice Subscription: B2B healthcare platform revenue from hospital subscriptions for BioTwin analysis and clinical intelligence interface. Pricing appears quote-based given enterprise nature and pilot-first sales motion.
2. Multi-Omics Lab Processing: Revenue from multi-omics sample processing via global lab network. Samples collected locally, processed in certified labs, results flowing into clinical interface.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Vizzhy fundamentally sells a cloud-based clinical decision support platform called BioTwin, which computes a patient's biological terrain by integrating twelve or more multi-omics and clinical data layers, and exposes the resulting insights through the Clinical Cognition Interface (CCI) to cardiologists and hospital systems. On top of this core engine, it offers execution modules for drug selection, care sequencing, nutrition guidance, exercise safety, and sensor-based monitoring, enabling cardiology providers to deliver longitudinal, biology-grounded precision cardiac care.

Product overview

Vizzhy is a preventive health intelligence platform focused on cardiac and cardiometabolic health. The core offering is the BioTwin—a multi-omics computed biological model integrating 12+ biological layers (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, microbiome, imaging, sensors, and clinical records) to compute disease drivers and reveal hidden mechanisms. The platform is delivered through a Clinical Cognition Interface (physician-facing console) with three execution layers: Precision Drug Layer (Rx) for multi-layer drug assessment, Care Sequencing for time-ordered care planning, Nutrition Guidance (Nutr) for patient-specific diet recommendations, Exercise Safety (Move) for exercise prescription safety, and Sensor Monitoring (Sens) for continuous physiological tracking. The platform operates independently without EMR dependency and integrates sample collection processed through certified labs.

Differentiator

Problem solved

Functional benefit

Products and services

• BioTwin A cloud-based computed biological model that integrates twelve or more multi-omics and clinical layers (genomics, transcriptomics, proteomics, metabolomics, microbiomics, phenotyping, etc.) into a unified terrain view of a cardiac patient, sold to hospitals and cardiology practices to enable precision, biology-grounded cardiac care.
• Clinical Cognition Interface (CCI) A clinical decision support software interface for cardiologists that surfaces hidden disease mechanisms, Terrain State scores, and precision treatment guidance derived from BioTwin's multi-omics computation.
• Precision Drug Layer (Rx) An execution module of the Clinical Cognition Interface that supports cardiologists in selecting and personalizing drug therapy based on the patient's BioTwin-derived biological terrain.
• Care Sequencing An execution module of the Clinical Cognition Interface that sequences cardiology care steps and longitudinal interventions based on the patient's biological terrain.
• Nutrition Guidance (Nutr) An execution module of the Clinical Cognition Interface that translates BioTwin-derived biological insights into personalized nutrition guidance for cardiac patients.
• Exercise Safety (Move) An execution module of the Clinical Cognition Interface that derives safe, biology-based exercise recommendations for cardiac patients from their BioTwin terrain.
• Sensor Monitoring (Sens) An execution module of the Clinical Cognition Interface that integrates sensor or wearable inputs with the BioTwin biological terrain to support continuous, biology-aware cardiac monitoring.

Quantifiable outcome

• Standard Labs + Imaging reveals ~5% of biological drivers; Genomics (Inherited Blueprint) ~16%; Gene Expression + Protein Activity ~42%; Metabolism + Epigenetics + Microbiome ~68%; Vizzhy's Full Biological Terrain 100%
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Tempus AI: Tempus is a leading AI-powered precision medicine company that integrates multi-modal data (genomics, transcriptomics, imaging, clinical records) to support clinical decision-making. It is the most direct large-scale peer to Vizzhy's multi-omics clinical intelligence platform, with substantially deeper capital, lab infrastructure, and enterprise health system penetration.
• Human Longevity Inc. Human Longevity offers whole-genome sequencing combined with advanced imaging, metabolomics, and clinical biomarkers to build comprehensive health intelligence profiles. It is a direct peer to Vizzhy in offering multi-omics-driven preventive health intelligence, though HLI focuses on executive/premium health rather than cardiology specifically.
• Color Health: Color Health combines genomics, clinical data, and digital health infrastructure to deliver population-scale preventive health programs, including cardiovascular risk assessment. It is a direct peer in multi-omics-enabled preventive health delivery to enterprise and provider customers, with established health system partnerships.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling and molecular information to support cancer care. While primarily oncology-focused, it represents the established model of multi-omics + clinical intelligence that Vizzhy extends into cardiometabolic care, with deep regulatory clearances and biopharma partnerships.
• Verily (Alphabet): Verily (an Alphabet life sciences company) builds precision health platforms combining multi-omics, sensor data, and clinical evidence. It competes with Vizzhy at the platform level with substantially greater resources, and overlaps on cardiometabolic and preventive health use cases.

Emerging players

• Arivale: Arivale was a consumer-focused multi-omics wellness platform combining genomics, metabolomics, and clinical markers with coaching. Although it has wound down, it remains a relevant comparable in the multi-omics preventive health category that Vizzhy is targeting in its cardiology application.
• Viome Life Sciences: Viome uses metatranscriptomic (microbiome and host gene expression) analysis combined with AI to provide personalized nutrition and health recommendations. It is an emerging player in the multi-omics-driven personalized health space, with a consumer/DTC orientation and similar biological terrain thesis.
• DayTwo: DayTwo provides microbiome-based personalized nutrition recommendations for glycemic control and metabolic health. It overlaps with Vizzhy's cardiometabolic prevention thesis and applies a partial multi-omics approach (microbiome + CGM) at a smaller scale.
• Cardiogram: Cardiogram applies AI to wearable sensor data (heart rate, sleep, activity) for cardiovascular risk detection. It is an emerging player in the cardiometabolic AI space and overlaps with Vizzhy's sensor-coupling approach, though operating at a narrower data modality.
• PrediSurge: PrediSurge (formerly Implicity) provides AI-driven cardiovascular risk prediction leveraging clinical and device data. It represents a category of specialized AI cardiac risk platforms that Vizzhy would compete with for cardiologist mindshare and budget, though operating at a smaller data scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vizzhyvsk
• Instagraminstagram.com/vizzhy_healthcare
• Xx.com/vizzhy_health
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vizzhy